Painkillers

Gut microbiome
#Drug delivery #Gut microbiome #Microbiome #Nanoparticles #Painkillers

New microbiome and nanoparticle research could help treat gut pain

Recent discoveries into gut bacteria and nanomedicines could pave the way for better treatments of gut pain, new research suggests.  According to studies published in Cell Host & Microbe and Proceedings of the National Academy of Sciences (PNAS), scientists have discovered a new… Read More

#News

Bottles of painkillers
#Painkillers

Research paves way for safer pain relief drugs

New research by scientists at the NYU Pain Research Center could help to develop more selective drugs to treat pain with fewer side effects, it has been revealed.  The research, published in the journal Nature Communications, identified which receptor in prostaglandins, the hormone-like substance targeted… Read More

#News

Chained to fibromyalgia concept
#Chronic pain #Drug discovery #Fibromyalgia #Medicinal cannabis #Painkillers

Where are the new drugs for fibromyalgia?

DDW’s Diana Spencer reviews the latest research into fibromyalgia treatment and the new therapies currently in development.  With no existing cure for fibromyalgia, a chronic pain syndrome, current treatments focus on managing the symptoms like pain, fatigue and poor sleep, with exercise being a key part of… Read More

#Exclusive Content

Hand pointing on human skeleton at low back
#Chronic pain #Painkillers #Persica Pharmaceuticals #Phase I trial

Trial offers an alternative to long-term opioid use for pain relief

Persica Pharmaceuticals has announced positive topline data from its Phase Ib Modic Trial for PP353, a drug candidate with the potential to offer patients an alternative to long-term opioid use for pain relief by targeting the cause of the pain rather than the symptoms.  The trial is… Read More

#News

#Antibiotics #Autoimmune disease #Genetics / genomics #Oncology #Painkillers #T cell engagers

New DDW Highlights podcast: 25 November 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s most exciting news stories all represent innovative solutions to the… Read More

#News

#Antibiotics #Autoimmune disease #Genetics / genomics #Oncology #Painkillers #T cell engagers

This week in drug discovery (18-22 November) 

News round-up for 18-22 November by DDW Senior Digital Content Editor Diana Spencer. This week’s most exciting news stories all represent innovative solutions to the treatment of disease, proving that ‘thinking outside the box’ can by the key to success in drug discovery. The top stories:… Read More

#News

Stomach pain
#Chronic pain #Irritable Bowel Syndrome #Painkillers #Peptides #University of Queensland

Highly promising new oral approach to abdominal pain

University of Queensland (UQ) researchers have developed a new class of oral painkillers to suppress chronic abdominal pain that is based on the peptide hormone oxytocin. The team changed the chemical structure of oxytocin to make it gut-stable after earlier work revealed the hormone could treat… Read More

#News #Trending News

Back pain
#Chronic pain #Drug abuse #FDA #Opioids #Painkillers #Protega

FDA approves abuse-deterrent immediate-release 10mg opioid

The US Food and Drug Administration (FDA) has approved Roxybond (oxycodone hydrochloride) 10mg for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The approval makes Roxybond the first FDA-approved abuse-deterrent immediate release (IR) 10mg oxycodone formulation… Read More

#News #Regulatory

Pain killers
#Drug development #Ensysce Biosciences #Opioids #Painkillers #Public health

In Conversation With: Dr Lynn Kirkpatrick, Ensysce Biosciences

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr Lynn Kirkpatrick, CEO… Read More

#News

Predicting analgesic compounds based on a two amino acids peptide to treat chronic pain.
#Chronic pain #New York University #Painkillers #Preclinical investigations #Small molecules

NYU scientists discover promising new candidate for pain treatment

A new compound reversed four types of chronic pain in animal studies, according to research led by New York University (NYU) College of Dentistry’s Pain Research Center. The small molecule, which binds to an inner region of a calcium channel to indirectly regulate it, outperformed gabapentin… Read More

#News

Neurons in the brain
#Algiax Pharmaceuticals #Neurology #Neuroscience #Painkillers #Phase II trial #Trial data

Phase IIa trial expanded for promising neuropathic pain drug

The independent Data Monitoring Committee (DMC) has recommended the continuation of Algiax Pharmaceuticals’ Phase IIa study with lead candidate AP-325 in chronic neuropathic pain. Based on the positive DMC review and confirmed financial commitment from its investors, the company will expand the trial to Belgium, France,… Read More

#News

Back pain
#Chemical engineering #Mouse models #Painkillers #Preclinical investigations

Researchers modify anti-nausea drug to treat pain

Altering the chemical properties of an anti-nausea drug enables it to enter an interior compartment of the cell and provide long-lasting pain relief, according to a new study led by researchers at NYU College of Dentistry’s Pain Research Center. The study, published in the Proceedings of… Read More

#News

Bottles of painkillers
#Painkillers #Precision medicine

Targeted painkillers could reduce side effects 

A University of Queensland spin-off company hopes to develop precision painkillers that are more accurate and less harmful to the liver. Professor Trent Munro, from the Australian Institute for Bioengineering and Nanotechnology (AIBN), is the scientific co-founder of Cassowary Pharmaceuticals, which is creating a new range of hyper-targeted… Read More

#News